文献速递糖尿病

恩格列净对2型糖尿病合并确诊心血管疾病患者尿白蛋白与肌酐比值的影响:EMPA-REG OUTCOME随机安慰剂对照试验的探索性分析

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-06-27

EMPA-REG OUTCOME试验的探索性分析纳入7028例2型糖尿病合并确诊心血管疾病患者,按基线白蛋白尿状态分组,比较恩格列净(10mg或25mg)与安慰剂对尿白蛋白与肌酐比值(UACR)的影响。第12周时,恩格列净组UACR较基线的降幅在正常白蛋白尿组为-7%、微量白蛋白尿组为-25%、大量白蛋白尿组为-32%,长期治疗至164周时降幅维持。停药后,微量及大量白蛋白尿组UACR仍低于安慰剂组,正常白蛋白尿组则无差异。

要点

  • 恩格列净在正常、微量及大量白蛋白尿三组中均降低UACR,第12周降幅分别为-7%、-25%、-32%,长期维持至164周。
  • 恩格列净组微量白蛋白尿持续改善为正常白蛋白尿的HR为1.43,大量白蛋白尿持续改善为微量或正常白蛋白尿的HR为1.82。
  • 恩格列净组正常白蛋白尿持续恶化为微量或大量白蛋白尿的HR为0.84。

核心结论

  • 这些结果支持恩格列净对尿白蛋白排泄的短期和长期获益,且不依赖于患者基线白蛋白尿状态。

研究设计与样本

  • EMPA-REG OUTCOME是一项在42个国家590个中心开展的随机、双盲、安慰剂对照试验。
  • 患者按1:1:1随机分配至恩格列净10mg、恩格列净25mg或安慰剂,在标准治疗基础上给药,直至至少691例患者发生主要结局的裁定事件。
  • 随机化按HbA1c、BMI、地区及估算肾小球滤过率分层,患者、研究者及数据分析人员对治疗分配设盲。
  • 本探索性分析按基线白蛋白尿状态(正常白蛋白尿:UACR<30mg/g;微量白蛋白尿:UACR≥30至≤300mg/g;大量白蛋白尿:UACR>300mg/g)比较恩格列净汇总组与安慰剂的UACR数据。
  • 2010年9月1日至2013年4月22日期间,共随机分配7028例患者,7020例接受治疗;基线有UACR数据的患者为6953例。

主要发现

  • 基线时,正常白蛋白尿组4171例(占接受治疗患者的59%;安慰剂组1382例,恩格列净组2789例),微量白蛋白尿组2013例(29%;安慰剂组675例,恩格列净组1338例),大量白蛋白尿组769例(11%;安慰剂组260例,恩格列净组509例)。
  • 中位治疗持续时间为2.6年(IQR 2.0-3.4;136周),中位观察时间为3.1年(IQR 2.2-3.6;164周)。
  • 第12周短期治疗后,恩格列净组UACR较基线变化的安慰剂校正几何均值比在正常白蛋白尿组为-7%(95%CI -12至-2;p=0.013),微量白蛋白尿组为-25%(95%CI -31至-19;p<0.0001),大量白蛋白尿组为-32%(95%CI -41至-23;p<0.0001)。
  • 第164周长期治疗时,恩格列净组三个组的UACR降幅均较安慰剂维持。
  • 停药后中位随访34或35天时,基线微量白蛋白尿组恩格列净较安慰剂UACR相对变化的安慰剂校正调整几何均值比为-22%(95%CI -32至-11;p=0.0003),大量白蛋白尿组为-29%(95%CI -44至-10;p=0.0048),正常白蛋白尿组为1%(95%CI -8至10;p=0.8911)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In a pooled analysis of short-term trials, short-term treatment with the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin reduced albuminuria in patients with type 2 diabetes and prevalent albuminuria. In this exploratory analysis of the EMPA-REG OUTCOME trial, we report the short-term and long-term effects of empagliflozin on albuminuria in patients with type 2 diabetes and established cardiovascular disease, according to patients' baseline albuminuria status. METHODS: In this randomised, double-blind, placebo-controlled trial at 590 sites in 42 countries, we randomly assigned patients aged 18 years and older with type 2 diabetes and established cardiovascular disease (1:1:1) to empagliflozin 10 mg, empagliflozin 25 mg, or placebo in addition to standard of care until at least 691 patients experienced an adjudicated event included in the primary outcome. We did the randomisation with a computer-generated random-sequence and interactive voice-response and web-response system, stratified by HbA1c, BMI, region, and estimated glomerular filtration rate. Patients, investigators, and individuals involved in analysis of trial data were masked to treatment assignment. The primary and secondary efficacy and safety endpoints of this trial have been reported previously. Here, we report urinary albumin-to-creatinine ratio (UACR) data for the pooled empagliflozin group versus placebo according to albuminuria status at baseline (normoalbuminuria: UACR <30 mg/g; microalbuminuria: UACR ≥30 to ≤300 mg/g; and macroalbuminuria: UACR >300 mg/g). We did the analysis with mixed-model repeated measures including prespecified and post-hoc tests. This study is completed and registered with ClinicalTrials.gov, number NCT01131676. FINDINGS: Between Sept 1, 2010, and April 22, 2013, we randomly assigned 7028 patients to treatment groups and 7020 patients received treatment. At baseline, we had UACR data for 6953 patients: 4171 (59% of treated patients; 1382 assigned to placebo and 2789 assigned to empagliflozin) had normoalbuminuria, 2013 (29%; 675 assigned to placebo and 1338 assigned to empagliflozin) had microalbuminuria, and 769 (11%; 260 assigned to placebo and 509 assigned to empagliflozin) had macroalbuminuria. Median treatment duration was 2·6 years (IQR 2·0-3·4; 136 weeks) and median observation time was 3·1 years (2·2-3·6; 164 weeks). After short-term treatment at week 12, the placebo-adjusted geometric mean ratio of UACR change from baseline with empagliflozin was -7% (95% CI -12 to -2; p=0·013) in patients with normoalbuminuria, -25% (-31 to -19; p<0·0001) in patients with microalbuminuria, and -32% (-41 to -23; p<0·0001) in patients with macroalbuminuria. The reductions in UACR were maintained with empagliflozin in all three groups compared with placebo during long-term treatment when measured at 164 weeks. At follow-up, after cessation of treatment for a median of 34 or 35 days, UACR was lower in the empagliflozin versus placebo group in those with baseline microalbuminuria (placebo-corrected adjusted geometric mean ratio of relative change from baseline with empagliflozin: -22%, 95% CI -32 to -11; p=0·0003) or macroalbuminuria (-29%, -44 to -10; p=0·0048), but not for patients with baseline normoalbuminuria (1%, -8 to 10; p=0·8911). Patients treated with empagliflozin were more likely to experience a sustained improvement from microalbuminuria to normoalbuminuria (hazard ratio [HR] 1·43, 95% CI 1·22 to 1·67; p<0·0001) or from macroalbuminuria to microalbuminuria or normoalbuminuria (HR 1·82, 1·40 to 2·37; p<0·0001), and less likely to experience a sustained deterioration from normoalbuminuria to microalbuminuria or macroalbuminuria (HR 0·84, 0·74 to 0·95; p=0·0077). The proportions of patients with any adverse events, serious adverse events, and adverse events leading to discontinuation increased with worsening UACR status at baseline, but were similar between treatment groups. The proportion of patients with genital infections was greater with empagliflozin than placebo in all subgroups by UACR status. INTERPRETATION: These results support short-term and long-term benefits of empagliflozin on urinary albumin excretion, irrespective of patients' albuminuria status at baseline. FUNDING: Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017. PMID: 28666775. doi:10.1016/S2213-8587(17)30182-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。